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Abstract
Clinicians will argue that cancer can only really receive the treatment that is needed through
thorough understanding of medicine. However, even empirical approaches to therapy result in
experimental analysis of the agencies involved on test cells, usually in culture. From the obverse
perspective, cell biologists will argue that until we fully understand cell cycle regulation, tumour
management will be too imprecise to make the best advances. A forum is needed whereby the
fundamental studies on cells prior to, during and after transformation in vitro can be freely
reported (open access) and discussed. The action of anticancer agents and cancer preventative
substances can more easily be studied in vitro before the often excessive complexity of making
similar studies in experimental and human cancers is tackled. Cancer Cell International is committed
to providing such a forum. Ironically within a few months of launching this open access journal,
Elsevier had much the same idea, and there one has to pay for the privilege of downloading vital
papers in this biomedical field.
Cancer journals have an interesting history. Many of them
are the official journals from established institutions or
societies that have a fine track record in research and med-
ical practice, with an avid and faithful readership. There
are probably more journals devoted to cancer than any
other field of medical science. The reason is obvious in
that cancer is a scourge, a disease that manifests itself in a
vast array of different forms and affects young and old
human beings, animals, and plants. Perhaps one of the
most remarkable things in the whole of biology is the
development of an adult organism from an egg, but dur-
ing this process or at some stage after it is complete, some
cells lose their co-ordinates and start to grow anomalously
in a relatively unregulated manner. They will continue to
grow in circumstances where normal cells would be con-
strained. So the problem being addressed is one that
comes down to the very heart of cellular biology, to the
regulation of the cell cycle, the process of differentiation
and the control at the next level of organisation in the
development of tissues, organs and bodies. Why is it that
cancer cells carry on dividing under circumstances where
normal cells become constrained? It is a keen academic
problem because we seek to find out from the pathology
what has gone wrong.
In many ways, advances in cancer research have been
rapid largely because we have begun to understand funda-
mental cell cycle control, genetic alterations consistent
with transformation, and the ways in which drugs interact
with tumour as well as normal cells. Controversy contin-
ues; some believe it is not so much that a series of lesions
occur within individual cells themselves as a case of inap-
propriate communication that leads to "a society of cells"
breaking away from the "normal" constraints when cer-
tain stresses are placed upon them. Looked at this way, it
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is perhaps surprising that cancer is not even more rife than
we find, especially among longer lived species.
Whatever way we wish to view cancer, it continues to
attract good research funding because, although cancer is
not the major killer amongst mankind, it is a frightening
(malignant) disorder that has for many years not seen
novel and better therapies emerging An exception is seen
with cervical cancer, but the cost of regular screening and
reading of exfoliative cytology samples is both a time-con-
suming and expensive business, which was supported
from early days and has traditionally been maintained.
Much work can be done not only on human and animals
cells that have a malignant phenotype, but on quite
remote organisms such as yeast and fungi, which give
information about control mechanisms and their
derangement. The use of animals to test carcinogens and
cancer drugs has been drastically reduced, bringing cell
models including spheroids (3-D cultures) much more
into vogue. The number of articles being produced on
cancer each year around the world has reached quite phe-
nomenal proportions, with many journals being devoted
to it. But some of those that in recent times used to "serve"
the grass-root work on fundamental cancer research have
become increasingly selective, in that average to good
studies are seen as not sufficiently high profile for the
prestigious pages of the best known journals. The result is
that many researchers will inevitably have to seek other
journals that do not indulge so heavily in "cherry-pick-
ing". We also need to have fast publication with open
access to the readers without the need to pay (the Varmos
principle).
Cancer Cell International was set up with the specific inten-
tion of addressing some of the above problems, and was
one of the very first niche or specialist – and now referred
to as "independent" journals – at BioMed Central http://
www.biomedcentral.com. My aim has been to have a
journal immediately available to everyone worldwide
through the internet that is devoted to the cellular
aspects of cancer. Some four months after launch, Else-
vier had the same idea and launched Cancer Cell. Cell
Press, now part of Elsevier, had developed a strong track
record with its publication of Cell and Neuron. Our posi-
tion turned almost immediately into a David and Goliath
encounter, and the saving grace of David persisting is that
you have the continued opportunity of an online, imme-
diately accessible, free of charge journal, unlike Cancer
Cell, which is both exclusive and expensive. Compare the
costs of getting a paper into Cancer Cell – if you are so
lucky – with that of getting it into Cancer Cell International.
[Forget for a moment the impact factor problem – almost
all articles wherever published can be accessed one way or
another these days, so it's the article that counts, not the
journal.] I call upon those of you who do good scientific
work in the field of cancer cell biology to submit manu-
scripts online to us, and have the type of journal that
meets modern demands fairly across the board and for
countries less advantaged than those privileged ones of
North American and Western Europe. It will not exclude
the average and good in order to concentrate on the best.
It will review all papers fairly, wherever they come from.
We have no page limit on the number of papers we can
publish per month or year. Colour is not an issue, and you
retain the copyright of your article. So, why not make the
most of this opportunity. We would greatly appreciate
seeing your reports, and if you need presubmission
appraisal, we can advise you on this matter before you
submit online.Page 2 of 2
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